Petros Pharmaceuticals (PTPI) Competitors $0.06 -0.06 (-49.03%) Closing price 03:59 PM EasternExtended Trading$0.06 +0.00 (+1.74%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTPI vs. HEPA, EVFM, TRVN, NMTR, SYRS, BPTSY, ATXI, VIRX, BIOR, and MYMDShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Hepion Pharmaceuticals (HEPA), Evofem Biosciences (EVFM), Trevena (TRVN), 9 Meters Biopharma (NMTR), Syros Pharmaceuticals (SYRS), Biophytis (BPTSY), Avenue Therapeutics (ATXI), Viracta Therapeutics (VIRX), Biora Therapeutics (BIOR), and MyMD Pharmaceuticals (MYMD). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. Hepion Pharmaceuticals Evofem Biosciences Trevena 9 Meters Biopharma Syros Pharmaceuticals Biophytis Avenue Therapeutics Viracta Therapeutics Biora Therapeutics MyMD Pharmaceuticals Petros Pharmaceuticals (NASDAQ:PTPI) and Hepion Pharmaceuticals (NASDAQ:HEPA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation, dividends and community ranking. Does the media favor PTPI or HEPA? In the previous week, Petros Pharmaceuticals had 2 more articles in the media than Hepion Pharmaceuticals. MarketBeat recorded 2 mentions for Petros Pharmaceuticals and 0 mentions for Hepion Pharmaceuticals. Petros Pharmaceuticals' average media sentiment score of 0.69 beat Hepion Pharmaceuticals' score of 0.00 indicating that Petros Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Petros Pharmaceuticals Positive Hepion Pharmaceuticals Neutral Does the MarketBeat Community prefer PTPI or HEPA? Hepion Pharmaceuticals received 20 more outperform votes than Petros Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Petros Pharmaceuticals an outperform vote while only 67.74% of users gave Hepion Pharmaceuticals an outperform vote. CompanyUnderperformOutperformPetros PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesHepion PharmaceuticalsOutperform Votes2167.74% Underperform Votes1032.26% Which has stronger valuation and earnings, PTPI or HEPA? Petros Pharmaceuticals has higher revenue and earnings than Hepion Pharmaceuticals. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Hepion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPetros Pharmaceuticals$5.11M0.03-$8.16M-$119.000.00Hepion PharmaceuticalsN/AN/A-$48.93M-$219.000.00 Which has more risk and volatility, PTPI or HEPA? Petros Pharmaceuticals has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500. Comparatively, Hepion Pharmaceuticals has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Do insiders & institutionals believe in PTPI or HEPA? 12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 17.2% of Hepion Pharmaceuticals shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 4.7% of Hepion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is PTPI or HEPA more profitable? Petros Pharmaceuticals' return on equity of -78.22% beat Hepion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Petros PharmaceuticalsN/A -78.22% -23.50% Hepion Pharmaceuticals N/A -812.56%-207.31% SummaryPetros Pharmaceuticals beats Hepion Pharmaceuticals on 11 of the 13 factors compared between the two stocks. Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$135,000.00$6.51B$5.38B$8.42BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.018.9726.6219.77Price / Sales0.03253.27392.02116.56Price / CashN/A65.8538.2534.62Price / Book0.026.486.814.53Net Income-$8.16M$143.98M$3.23B$248.18M7 Day PerformanceN/A3.37%4.05%1.06%1 Month PerformanceN/A7.83%11.64%14.68%1 Year PerformanceN/A-2.24%17.11%6.87% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros Pharmaceuticals0.8081 of 5 stars$0.06-49.0%N/A-99.2%$135,000.00$5.11M-0.0120News CoverageEarnings ReportGap DownHigh Trading VolumeHEPAHepion PharmaceuticalsN/A$0.10-12.4%N/A-99.9%$1.06MN/A-0.0220Gap UpEVFMEvofem Biosciences0.1891 of 5 stars$0.01+1.1%N/A-37.1%$1.05M$11.39M-0.01120News CoverageTRVNTrevena1.3408 of 5 stars$1.20-4.0%$5.00+316.7%-89.2%$1.04M$443,000.00-0.0340Gap DownNMTR9 Meters BiopharmaN/AN/AN/AN/A$1.04MN/A-0.0220SYRSSyros Pharmaceuticals2.1092 of 5 stars$0.03-14.2%$3.33+10,901.1%-99.5%$813,000.00$386,000.00-0.01120Gap UpBPTSYBiophytisN/A$2.08flatN/AN/A$730,000.00N/A0.0030ATXIAvenue Therapeutics1.0169 of 5 stars$0.22flatN/A-94.2%$701,000.00N/A0.014Gap UpVIRXViracta Therapeutics1.1972 of 5 stars$0.02flat$4.06+23,797.1%-97.9%$676,000.00N/A-0.0220Gap UpBIORBiora Therapeutics1.8269 of 5 stars$0.14flat$23.00+16,937.0%-97.9%$611,000.00$892,000.00-0.01120MYMDMyMD PharmaceuticalsN/A$0.19-4.3%N/A-92.1%$448,000.00N/A0.006High Trading Volume Related Companies and Tools Related Companies Hepion Pharmaceuticals Competitors Evofem Biosciences Competitors Trevena Competitors 9 Meters Biopharma Competitors Syros Pharmaceuticals Competitors Biophytis Competitors Avenue Therapeutics Competitors Viracta Therapeutics Competitors Biora Therapeutics Competitors MyMD Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTPI) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
